Caplin Point Laboratories Ltd

Net profit of Caplin Point Laboratories rose 18.08% to Rs 154.45 crore in the quarter ended September 2025 as against Rs 130.80 crore during the previous quarter ended September 2024. Sales rose 10.54% to Rs 534.04 crore in the quarter ended September 2025 as against Rs 483.10 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales534.04483.10 11 OPM %35.4234.08 - PBDT219.40185.22 18 PBT201.00168.46 19 NP154.45130.80 18 Powered by Capital Market - Live

Net profit of Caplin Point Laboratories declined 2.98% to Rs 102.59 crore in the quarter ended September 2025 as against Rs 105.74 crore during the previous quarter ended September 2024. Sales declined 15.75% to Rs 175.18 crore in the quarter ended September 2025 as against Rs 207.93 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales175.18207.93 -16 OPM %43.3047.21 - PBDT135.02141.15 -4 PBT129.00134.66 -4 NP102.59105.74 -3 Powered by Capital Market - Live

Caplin Point Laboratories will hold a meeting of the Board of Directors of the Company on 5 November 2025.Powered by Capital Market - Live

The said drug is equivalent to reference listed drug (RLD) from Hikma International Pharmaceuticals LLC. Nicardipine Hydrochloride in 0.9% Sodium Chloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable. According to IQVIA (IMS Health), Nicardipine Hydrochloride in Sodium Chloride injection had US sales of approximately $68 million for the 12-month period ending August 2025. The company recently acquired the four approved ANDA products, Icatibant Acetate Injection, Paricalcitol Injection, Gatifloxacin Ophthlamic Solution and Ketamine Hydrochloride Injection from third parties. According to IQVIA (IMS Health), the collective market size for the above products in the US is approximately $121 million for the 12-month period ending August 2025. These products will be introduced into US and other markets in 2026. Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc. The company reported an 11.2% year-on-year (YoY) increase in revenue from operations to Rs 510.2 crore and a 20.7% YoY rise in profit after tax (PAT) to Rs 150.8 crore in Q1 FY26. The scrip declined 1.18% to Rs 2002.40 on the BSE.Powered by Capital Market - Live

Caplin Steriles (Caplin), a subsidiary company of Caplin Point Laboratories, has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Milrinone Lactate in 5% Dextrose Injection, 20 mg/100 mL (0.2 mg/mL) and 40 mg/200 mL (0.2 mg/mL) Single-dose Infusion Bags, a generic therapeutic equivalent version of the Reference Listed Drug (RLD) PRIMACOR in Dextrose 5%, by Sanofi Aventis US LLC. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. According to IQVIATM (IMS Health), Milrinone Lactate in 5% Dextrose Injection had US sales of approximately $11 million for the 12-month period ending July 2025. Powered by Capital Market - Live

The approval covers two dosage forms'20 mg/100 mL (0.2 mg/mL) and 40 mg/200 mL (0.2 mg/mL)'in single-dose infusion bags. The product is a generic therapeutic equivalent version of the Reference Listed Drug (RLD), PRIMACOR in Dextrose 5%, by Sanofi Aventis US LLC. Milrinone is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. According to IQVIATM (IMS Health), Milrinone Lactate in 5% Dextrose Injection had US sales of approximately $11 million for the 12-month period ending July 2025. Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc. The company reported an 11.2% year-on-year (YoY) increase in revenue from operations to Rs 510.2 crore and a 20.7% YoY rise in profit after tax (PAT) to Rs 150.8 crore in Q1 FY26. Powered by Capital Market - Live

Caplin Point Laboratories announced that the 34th Annual General Meeting(AGM) of the company will be held on 22 September 2025.Powered by Capital Market - Live

Caplin Point Laboratories announced that the Board of Directors of the Company at its meeting held on 7 August 2025, inter alia, have recommended the final dividend of Rs 3 per equity Share (i.e. 150%) , subject to the approval of the shareholders.Powered by Capital Market - Live

Caplin Point Laboratories has fixed 12 September 2025 as record date for payment of final dividend for FY 2024-25, if declared. Powered by Capital Market - Live

The company reported an 11.2% rise in revenue from operations to Rs 510.2 crore in Q1 FY26. Profit before tax jumped 19.5% YoY to Rs 184.5 crore, while profit after tax (PAT) rose 20.7% to Rs 150.8 crore. EBITDA came in at Rs 200.9 crore, growing 17.9% YoY, with the EBITDA margin expanding to 37.7% from 35.7% in Q1 FY25. Operationally, cash flow from operations rose to Rs 118 crore, up from Rs 96 crore in Q1 FY25, a 22.9% YoY increase. Compared to Q4 FY25, revenue from operations grew by 1.5%, and total revenue improved by 1.0%. Gross profit increased by 4.6%, while EBITDA rose 3.7% QoQ. Profit before tax increased 4.4% sequentially, and PAT saw a 3.8% rise, reflecting continued earnings momentum. The company continues to derive the bulk of its revenue from international markets, with 79% coming from emerging markets like Latin America and Africa, and the remaining 21% from the United States. C.C. Paarthipan, chairman said: We're putting in place the right building blocks for both Emerging Markets and Regulated markets. We're making good progress with finalizing partners and also filing dossiers in our new key target markets of Mexico, Chile, USA etc. We're also aiming to gradually onshore some strategic manufacturing at important locations in Latin America and US, and taking the first steps of acquiring land/buildings for the same. We've also launched our second innings from China which will focus more deeply on high-tech products like Biosimilars, Peptides etc. We're strengthening our Marketing and Regulatory teams at both India and LatAm with seasoned professionals, to ensure our growth momentum remains steady. We continue to have a sharp focus on consolidating our presence in the existing markets with expansion on products, profits and cashflows. Caplin Point Laboratories is a pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. The company also has a growing presence in the regulated markets such as US through its subsidiary Caplin Steriles and Caplin Steriles USA Inc. Powered by Capital Market - Live